Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule
ADIL(NASDAQ:ADIL) GLEN ALLEN, Va., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has been granted a 180 calendar day extension from The Nasdaq Stock Market LLC (“Nasdaq”) to regain compliance with the Nasdaq's minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on Nasdaq (the “Minimum Bid Price Requirement”), following the expiration of the initial 180 calendar day period to regain compliance on September 1, 2025, which was initially granted on March 5, 2025.
Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
ADILGLEN ALLEN, Va., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the second quarter of 2025.
12 Health Care Stocks Moving In Wednesday's Intraday Session
ADILEXCLUSIVE: Adial Pharmaceuticals Lead Candidate For Alcohol Use Disorder Advances Toward Phase 3 Trial
ADILAdial refines Phase 3 plans for AD04 in Alcohol Use Disorder, focusing on genetic subgroups and leveraging Cytel's advanced trial design expertise.
EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Engages with Cytel's Machine Learning Technology on Data Analysis and Phase 3 Trial Design'
ADILEXCLUSIVE: Adial Pharmaceuticals Tells Benzinga Co. Advances Toward Phase III Development For AD04
ADILAdial Pharmaceuticals Q1 EPS $(0.34) Beats $(0.50) Estimate
ADILAdial Pharmaceuticals Received Milestone Payment From Adovate Following Initiation Of Phase 1 Study; Adial Eligible To Receive More Than $50M In Commercial Milestone Payments Plus Additional $11M In Development And Approval Milestone Payments Per Compound
ADILEXCLUSIVE: Adial Pharmaceuticals Secures FDA End of Phase 2 Meeting Request To Discuss Upcoming Clinical Development Plan For Lead Program
ADILFDA schedules End of Phase 2 meeting with Adial to discuss Phase 3 plans for AD04, its genetically targeted drug for Alcohol Use Disorder.
EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Meeting's Purpose is To Discuss Upcoming Clinical Development Plan and Protocol Designs'
ADILEXCLUSIVE: Adial Pharmaceuticals Tells Benzinga Co. Granted End Of Phase II Meeting From The U.S. FDA
ADIL12 Health Care Stocks Moving In Thursday's After-Market Session
ADILEXCLUSIVE: Adial Pharmaceuticals Expands Patent Portfolio With New US Patent For Lead Drug For Alcohol And Opioid Use Disorders
ADILAdial secures USPTO patent for AD04, expanding coverage to treat alcohol and opioid-related disorders in patients with genetic markers.
EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'New patent covers a treatment method for a broad spectrum of alcohol-related disorders, including additional conditions associated with alcohol use'
ADILEXCLUSIVE: Adial Pharmaceuticals Tells Benzinga Co. Expands Intellectual Property Portfolio With New US Patent Granted For Genetic-Based Treatment Of Alcohol And Opioid Use Disorders
ADIL12 Health Care Stocks Moving In Monday's After-Market Session
ADILAdial Pharmaceuticals FY 2024 GAAP EPS $(2.72) Beats $(2.97) Estimate
ADILEXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder
ADILAdial Pharmaceuticals secured FDA support for its AD04 bridging strategy, paving the way for Phase 3 trials in 2025 after confirming bioequivalence.
EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Adial moves forward with manufacturing of clinical supplies for upcoming Phase 3 clinical program in 2025'
ADILEXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'FDA feedback confirms Adial's proposed in vitro bridging strategy to the Phase 3 formulation to fulfill the bridging requirement for the 505(b)(2) regulatory registration pathway for approval'
ADILEXCLUSIVE: Adial Pharmaceuticals Tells Benzinga Co. Receives Response From FDA Meeting Regarding Proposed In Vitro Bridging Strategy For AD04
ADILAdial Pharmaceuticals shares are trading higher after the company was granted a U.S. patent covering claims focused on a method for identifying genetic markers in patients with alcohol or opioid-related disorders.
ADILAdial Pharmaceuticals Granted US Patent Covering Claims Which Focus On Method For Identifying Genetic Markers In Patients With Alcohol Or Opioid Related Disorders
ADILEXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders
ADILAdial Pharmaceuticals received a U.S. patent for genetic marker-based treatment methods and completed a pharmacokinetics study supporting its Phase 3 trial.
EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'New Patent expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence'
ADILEXCLUSIVE: Adial Pharmaceuticals Tells Benzinga Co. Awarded New U.S Patent Covering Genotype-Specific Treatment Of Opioid -Related Disorders
ADIL12 Health Care Stocks Moving In Thursday's Pre-Market Session
ADILEXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder
ADILAdial Pharmaceuticals completes PK study for AD04 in AUD, meeting FDA requirements and preparing for Phase 3 trial. Data supports 505(b)(2) application.
EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Continued excellent safety and tolerability findings, consistent with extensive human use experience with ondansetron'
ADILEXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Marks final study needed for the upcoming FDA meeting for the Phase 3 study design and ongoing partnership discussions'
ADILEXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Confirmed relative bioavailability to the reference standard, dose proportional increases in pharmacokinetic exposure, and no food effect'
ADILEXCLUSIVE: Adial Pharmaceuticals Tells Benzinga Co. Announces Results From AD04-103 Pharmacokinetics Study Of AD04 For The Treatment Of Alcohol USE Disorder
ADILRodman & Renshaw Initiates Coverage On Adial Pharmaceuticals with Buy Rating, Announces Price Target of $8
ADILAdial Pharmaceuticals Appoints Vinay Shah As Chief Financial Officer, Effective Nov. 16
ADILAdial Pharmaceuticals Announces Research Collaboration With UC San Diego To Advance Purnovate's Adenosine Compounds As Potential Treatments For Inflammatory Diseases & Disorders
ADIL